A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT01223313
First received: October 14, 2010
Last updated: January 14, 2013
Last verified: February 2012
  Purpose

WHAT IS THE FEMALE CONDOM? The female condom being examined in this study is investigational (experimental) and is not yet approved by the Food and Drug Administration (FDA). The female condom is made up of a pouch that adjusts to the shape of the vagina. The female condom that will be used in this study is not lubricated, but a water-based lubricant will be provided for you to use with it. Also, the female condoms used in this study will be provided to you at no cost.

WHY IS THIS STUDY BEING DONE?

The purpose of this study is to find out:

  • How well the female condom works to prevent pregnancy
  • How well the female condom works to prevent transmission of sexually transmitted diseases
  • How safe the female condom is to use
  • If urinary tract infections and symptomatic vaginal infections occur while using the female condom
  • How well women like the female condom
  • How well the female condom performs.

WHAT DOES THE STUDY INVOLVE? There will be approximately 10 clinics in the study with about 500 women from all over the United States participating in this study. You are being asked to participate in a research study because you are a woman between the ages of 18 and 40, are in general good health, have regular menstrual cycles, do not want to become pregnant for at least the next 7 months, and are willing to rely on the female condom as your primary method of contraception during study participation.

HOW LONG DOES THE STUDY LAST? Enrollment for this study is expected to last about 12 months. You will need to come to the clinic for a screening/admission visit and then 2 or more visits. You will also be asked to complete a diary every day about your use of the female condoms. The clinical staff will help set up your planned clinical visits during the study.


Condition Intervention Phase
Contraception
Device: Woman's Condom
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

Resource links provided by NLM:


Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Primary Outcome Measures:
  • Contraceptive Efficacy [ Time Frame: Determined at each visit. ] [ Designated as safety issue: No ]
    The primary objective of the study is to determine the contraceptive efficacy of the Woman's Condom (WC).


Secondary Outcome Measures:
  • Safety of the Woman's Condom [ Time Frame: All each visit ] [ Designated as safety issue: Yes ]
    Safety of the Woman's Condom using the safety data collected during the clinical trial.

  • Urinary tract infections (UTIs) and symptomatic vaginal infection [ Time Frame: At each visit ] [ Designated as safety issue: Yes ]
    Incidence of urinary tract infections (UTIs) and symptomatic vaginal infection.

  • Chlamydia trachomatis, Neisseria gonorrhea, or trichomoniasis. [ Time Frame: At each visit ] [ Designated as safety issue: Yes ]
    Incidence of acquisition of Chlamydia trachomatis, Neisseria gonorrhea, or trichomoniasis.

  • Acceptability of the Woman's Condom [ Time Frame: At each visit ] [ Designated as safety issue: No ]
    Acceptability of the Woman's Condom as measured by an acceptability questionnaire administered mid-study (visit 2, after menstrual cycle 3) and at study exit (visit 3, after menstrual cycle 6 or early discontinuation).

  • Performance of the Woman's Condom [ Time Frame: At each visit ] [ Designated as safety issue: No ]
    Performance of the Woman's Condom as assessed by self-reported total clinical failure and its components (clinical breakage, slippage, misdirection, and invagination).


Enrollment: 500
Study Start Date: January 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Woman's Condom
The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
Device: Woman's Condom
The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.

Detailed Description:

This is a Phase III multicenter, open-label, non-comparative trial of the Woman's Condom to evaluate contraceptive efficacy as the primary method of contraception. Secondary evaluations include safety assessment, incidence of UTIs, symptomatic vaginal infection, performance of the Woman's Condom (clinical breakage, slippage, misdirection, and invagination) and overall acceptability of the product. We will perform a Substudy to assess the semen biomarker as a means of detecting product failure in a subset of subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

To enroll into the clinical trial, potential subjects must:

  1. Be healthy women, who are sexually active, at risk for pregnancy and desiring contraception.
  2. Be within the age range of 18 through 40 years inclusive at enrollment.
  3. Have a negative urine pregnancy test at the admission visit.
  4. Have a history of regular cyclic menses with a usual length of 21 to 35 days when not using hormonal contraception.
  5. Have one menses after switching from oral contraceptives to using the Woman's Condom.
  6. Have at least one spontaneous menstrual cycle (two menses) following a pregnancy that ended at 14 or more weeks gestation.
  7. Have at least one cycle (two menses) after an abortion at less than 14 weeks gestation.
  8. Be willing to accept a risk of pregnancy.
  9. Be willing to engage in at least four acts of heterosexual vaginal intercourse per month for a period of 6 months.
  10. Be willing to only use the study product as the primary method of contraception over the course of the study.
  11. Be capable of using the study product properly and agree to observe all study directions and requirements.
  12. Be willing to keep a diary to record coital information, product use information, information about the use of other vaginal products, and any symptoms, which occurred in her or her partner over the course of study participation.
  13. Be willing to state that, to her best knowledge, her sexual partner(s):

    1. Has not had a vasectomy or been previously diagnosed as infertile.
    2. Has not been previously diagnosed or suspected of HIV unless he has subsequently had a negative HIV test.
    3. Has not been known to have engaged in homosexual intercourse in the past 5 years unless he has had negative HIV test results since then.
    4. Has not shared injection drug needles in the past unless he has had a negative HIV test at least 6 weeks since last use.
    5. Has no known history of allergy or sensitivity to polyurethane (condom pouch), polyvinyl alcohol (capsule), or other water-based lubricants such as Astroglide.
  14. Agree not to participate in any other clinical trials during the course of this study.
  15. Be willing to give written informed consent to participate in the trial.

Exclusion Criteria

To enroll into the clinical trial, potential subjects must not:

  1. Have a history of allergy or sensitivity to polyurethane (condom pouch), polyvinyl alcohol (capsule), or other water-based lubricants such as Astroglide.
  2. Have current UTI or symptomatic vaginal infection as confirmed by dipstick urinalysis, or if needed by a urine culture or wet mount (see Schedule of Assessments for definitions), unless treated and proof of cure is documented by a negative test result performed at least 2 weeks post-treatment.
  3. Have evidence of Chlamydia trachomatis or Neisseria gonorrhea infection unless she and her partner(s) complete treatment and proof of cure is documented for the subject only by a negative test result performed at least 3 weeks post-treatment.
  4. Be pregnant, have a suspected pregnancy or desire to become pregnant during the course of the study.
  5. Have a history of infertility or pelvic inflammatory disease without a subsequent spontaneous intrauterine pregnancy.
  6. Have been diagnosed with pelvic inflammatory disease (PID) without a subsequent intrauterine pregnancy.
  7. Be in a monogamous relationship of less than 4 months with their partner.
  8. Have any contraindications to pregnancy (medical condition) or regularly use category D or X or exclusionary medications listed in Appendix F.
  9. Have shared injection drug needles in the past unless has a negative HIV test at least 6 weeks since last use.
  10. Have known or suspected to have an HIV infection.
  11. Have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence (initial episode) within 3 months prior to screening or have clinical evidence of HSV on exam.
  12. Be lactating or breastfeeding.
  13. Have any clinically significant abnormal vaginal bleeding or spotting within the month prior to screening.
  14. Have had vaginal or cervical biopsy or vaginal surgery within 3 months prior to screening.
  15. Have used vaginal or systemic antibiotics or antifungal agents within 14 days prior to screening or enrollment.
  16. Have received a Depo-Provera® injection in the 9 months prior to enrollment (this exclusionary time period can be shortened to 6 months if the subject has also had 2 spontaneous menstrual cycles [requires minimum of 3 menses] that meet criteria for normal menstrual cycles).
  17. Have an abnormal Pap test based on the following criteria:

    • Pap test in the past 15 months with ASC-US unless:

      • less than 21 years of age;
      • a repeat Pap test at least 6 months later was normal;
      • reflex HPV testing was performed and was negative for high-risk HPV; or
      • a colposcopy (with or without biopsy) found no evidence of dysplasia requiring treatment or treatment was performed and follow-up at least 6 months after the treatment showed no evidence of disease;
    • Pap test in the past 15 months with LSIL unless:

      • less than 21 years of age;
      • a colposcopy (with or without biopsy) found no evidence of dysplasia requiring treatment or treatment was performed and follow-up at least 6 months after the treatment showed no evidence of disease;
    • Pap test in the past 15 months with ASC-H, atypical glandular cells, or HSIL unless colposcopy and/or treatment was performed and follow-up at least 6 months after the colposcopy and/or treatment showed no evidence of disease;
    • Pap test in the past 15 months with malignant cells.
  18. Have a past (within 12 months) or current history of alcohol or drug [recreational, prescription or over-the-counter (OTC)] abuse.
  19. Have taken an investigational drug or used an investigational device within the past 30 days.
  20. Have previously participated in or completed this study.
  21. Have issues or concerns (in the judgment of the investigator) that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study. For example, if the subject is found to have Condyloma Accuminata, the investigator can decide whether to exclude the subject or not, depending on its location and if use of the condom may be painful for the subject.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01223313

Locations
United States, California
California Family Health Council, Inc
Los Angeles, California, United States, 90010
United States, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
United States, New York
NYU Medical Center Family Planning
New York, New York, United States, 10016
Columbia University
New York, New York, United States, 10032
United States, Ohio
University of Cininnati College of Medicine
Cincinnati, Ohio, United States, 45267
United States, Oregon
Oregon Health Scieces University
Portland, Oregon, United States, 97239
United States, Pennsylvania
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104
Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
UT Southwestern Medical Center Dept. of OB/Gyn
Dallas, Texas, United States, 75390
United States, Virginia
Jones Institute of Reproductive Medicine
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT01223313     History of Changes
Other Study ID Numbers: CCN008
Study First Received: October 14, 2010
Last Updated: January 14, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
Contraception
Woman's Condom
Female Condom
Condom

Additional relevant MeSH terms:
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on April 21, 2014